#KidneyWk on X 20 hours ago

RT @biogen: #News: We announced positive Phase 2 results for our investigational treatment for people living with IgA nephropathy at #Kidne…

View Post

#KidneyWk on X 20 hours ago

RT @biogen: #News: We’re presenting new data on an investigational treatment for immunoglobulin A nephropathy (IgAN) at @ASNKidney #KidneyW…

View Post

#KidneyWk on X 20 hours ago

RT @biogen: Join us at @ASNKidney #KidneyWk to learn about our ongoing research in kidney disease and our late-stage clinical trials. Find…

View Post

#KidneyWk on X 20 hours ago

RT @VertexPharma: We are excited to share new data from multiple investigational kidney disease programs at the 2024 @ASNKidney Week Congre…

View Post

#KidneyWk on X 1 day ago

RT @rheault_m: Late breakers that included children: ✅Setanaxib in Alport (12+) Late breakers that did NOT include children: 🚫Atacicept i…

View Post

#KidneyWk on X 3 days ago

In this @Neph_Times video, nephrology expert John Gill, M.D., analyzes results presented at #KidneyWk from the Phase 2 BESTOW trial assessing our i...

View Post

#KidneyWk on X 3 days ago

ICYMI: RUBY-3 demonstrates that targeting BAFF and APRIL with povetacicept can drive proteinuria reduction and immunologic remission in IgAN and pM...

View Post

#KidneyWk on X Monday, December 22 @ 7:38 AM

RT @Neph_Times: SPRINT data show intensive BP control favors most CKD patients, with greatest net benefit in those with lower eGFR. #Kidney…

View Post

#KidneyWk on X Monday, December 22 @ 7:00 AM

Myda Khalid, MD, provides important takeaways from the recently published guidelines for #IgANephropathy, touching on data presented at Kidney Week...

View Post

#KidneyWk on X Monday, December 22 @ 4:45 AM

SPRINT data show intensive BP control favors most CKD patients, with greatest net benefit in those with lower eGFR. #KidneyWk #nephrology #CKD #hyp...

View Post